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Nance-Horan syndrome (NHS) is an X-linked disorder characterized by congenital cataracts, dental anomalies,
dysmorphic features, and, in some cases, mental retardation. NHS has been mapped to a 1.3-Mb interval on
Xp22.13. We have conﬁrmed the same localization in the original, extended Australian family with NHS and have
identiﬁed protein-truncating mutations in a novel gene, which we have called “NHS,” in ﬁve families. The NHS
gene encompasses ∼650 kb of genomic DNA, coding for a 1,630–amino acid putative nuclear protein.NHSorthologs
were found in other vertebrates, but no sequence similarity to known genes was identiﬁed. Themurine developmental
expression proﬁle of the NHS gene was studied using in situ hybridization and a mouse line containing a lacZ
reporter-gene insertion in the Nhs locus. We found a complex pattern of temporally and spatially regulated ex-
pression, which, together with the pleiotropic features of NHS, suggests that this gene has key functions in the
regulation of eye, tooth, brain, and craniofacial development.
Introduction
Nance-Horan syndrome (NHS [MIM 302350]) was ﬁrst
described independently in 1974, in Australia (Horan
and Billson 1974) and the United States (Nance et al.
1974), as an X-linked syndrome involving congenital
cataract and dental anomalies. Ophthalmological ﬁnd-
ings in affected males include bilateral severe congenital
cataract involving the fetal nucleus and posterior Y su-
ture with variable zonular extensions into the posterior
cortex, usually leading to profound visual loss and re-
quiring surgery. Microcornea, nystagmus, and microph-
thalmia have also been reported in some pedigrees
(Lewis et al. 1990; Stambolian et al. 1990; Walpole et
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al. 1990). Dental abnormalities include screwdriver
blade–shaped incisors, supernumerarymaxillary incisors
(mesiodens), and diastema (Walpole et al. 1990). Ap-
proximately 30% of affected males display mental re-
tardation and behavioral disturbance (Walpole et al.
1990; Toutain et al. 1997a), and several families were
reported to have lateral brachymetacarpalia (Lewis et al.
1990). Characteristic dysmorphic facial features, which
may be subtle, include large anteverted pinnae; long,
narrow facies; and prominent nose and nasal bridge
(Lewis et al. 1990; Walpole et al. 1990). The disorder
appears to be inherited in a codominant fashion, with
heterozygous females often manifesting similar but less
severe features than affected males, including posterior
Y-sutural cataracts, with little or no loss of vision, and
characteristic dental abnormalities (Walpole et al. 1990;
Zhu et al. 1990).
NHS was mapped to Xp21.1-p22.3 (Lewis et al.
1990; Stambolian et al. 1990) and, more recently, was
reﬁned to a critical region of 1.3 Mb between STR
markers DXS1195 and DXS999 (Toutain et al. 2002).
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We have independently conﬁrmed the same minimal ge-
netic interval by detailed analysis of the original Aus-
tralian family with NHS. A truncating mutation in a
novel gene, which we have called “NHS” (accession
number AY436752), was found in this pedigree, and,
subsequently, different truncating mutations have been
found in four other unrelated pedigrees with NHS.
Here, we present detailed expression data, in human and
mouse, conﬁrming a developmental expression pattern
consistent with a role in the pleiotropic features of NHS.
Subjects and Methods
Affected Individuals and Families Tested
Approval for this study was obtained from theHuman
Research Ethics Committees of the Royal Children’s
Hospital, Melbourne, the Royal Victorian Eye and Ear
Hospital, Melbourne, and the University of Tasmania,
Hobart, and the study adhered to the tenets of the Dec-
laration of Helsinki. Written informed consent was ob-
tained from all participating individuals or their guard-
ians. All available family members were examined by
one or more ophthalmologists (J.E.C., I.R.-E., M.G.W.,
D.A.M., J.E.E., A.N., or M.C.). DNA was extracted
from whole blood or buccal mucosa swabs through use
of the PureGene DNA Isolation Kit (Gentra Systems).
Database Analysis
Nucleotide and protein database searches were per-
formed, through the Web site of the National Cen-
ter for Biotechnology Information, by BLAST algo-
rithms BLASTN, BLASTX, and TBLASTX, against
the nonredundant dbEST, high-throughput genomic se-
quences, and species-speciﬁc databases. The putative
promoter was identiﬁed using the Neural Network Pro-
moter Prediction tool (Reese 2001), and subcellular lo-
calization of the putative NHS protein has been pre-
dicted using PSORTII (PSORT II Prediction Web site).
Zebraﬁsh data have been accessed via the Danio rerio
Sequencing Project Web page.
Genotyping and Linkage Analysis
All individuals were genotyped at seven microsatel-
lite loci within a 10-cM region on Xp22.31-p22.13 pre-
viously reported as linked to NHS (tel-DXS1224-
DXS1053-DXS1195-DXS418-DXS999-DXS365-
DXS989-cen) (Toutain et al. 1997b). An additional four
microsatellite markers—labeled as markers 1, 2, 3, and
4 in our data—were extracted from the draft genome
sequence and were genotyped in family 1 (primers avail-
able on request). Two-point linkage analysis was per-
formed with MLINK, part of the FASTLINK package
(Cottingham et al. 1993), and multipoint and haplotype
analyses were performed with X-linked GeneHunter
Plus (Kong and Cox 1997).
Mutation Analysis
Coding regions of all characterized genes in the critical
region (SCML1, RAI2, SCML2, STK9, RS1, and PPEF1)
were directly sequenced using an ABI PRISM 310 Ge-
netic Analyzer (Applied Biosystems), after PCR ampli-
ﬁcation and puriﬁcation with the Ultraclean PCR
cleanup kit (MoBio). The NHS candidate gene was
screened using intronic primers for the ampliﬁcation of
all identiﬁed exons (primer sequences available on re-
quest). Where possible, we conﬁrmed familial segrega-
tion of the NHS mutation. We tested 200 control chro-
mosomes for each mutation by restriction enzyme
analysis or by sequencing of both strands of the PCR
product.
Northern Blot Analysis
Northern blot analysis was performed on Human
Multiple Tissue Northern ﬁlters (human 12-lane MTN
blot Clontech and human Fetal II MTN blot Clontech),
by following the manufacturer’s protocol. The blots
were hybridized with three independent cDNA probes
derived from exon 6, exons 6–8, and the 3′ UTR of the
NHS gene and were radiolabeled with a[32P]-dATP by
random priming (details available on request). The
mouse northern blot (Seegene) contained 20 mg of total
RNA per lane, from mouse brain at various stages of
development. The probe was generated from the 3′ end
of the mouse Nhs gene. Hybridization was performed
in ExpressHyb solution (Clontech) at 68C, as per the
manufacturer’s instructions.
RT-PCR
RT-PCR was performed on oligo-dT–primed ﬁrst-
strand cDNA from human adult and fetal brain, lens,
retina, retinal pigment epithelium, placenta, lympho-
cytes, and ﬁbroblasts. A 206-bp fragment was ampliﬁed
with the forward primer RT-6 (5′-GAGACCCAAGGA-
AATGTGGA-3′) and the reverse primer RT-8 (5′-ATGT-
CCCCGGAATCTTTTCT-3′), designed to amplify a re-
gion of cDNA corresponding to the region from the end
of exon 6 to the beginning of exon 8. PCR was per-
formed using Hot Star Taq (Qiagen) at 95C for 15 min,
followed by 35 cycles of 94C for 30 s, 60C for 30 s,
and 72C for 30 s. Ampliﬁcation was performed on both
RT and RT templates.
Mouse In Situ Hybridization
Nonradioactive mouse embryo in situ hybridization
was performed as described elsewhere (Dunwoodie et al.
1997). Mouse embryonic and neonatal sections were hy-
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bridized with the sense and antisense RNA probes gen-
erated from regions of Nhs in exon 1 (genomic sequences
AL672082 and AC097354, Nhs5 probe; primers forward
[5′-GCCTTTCGCCAAGCGGATCG-3′] and reverse [5′-
GCCTCCTGCTTGGGGTCCAAC-3′]; amplicon of 549
bp) and exon 6 (genomic sequences AL732391 and
AC093447, Nhs4 probe; primers Fw [5′-CTCAGCTAG-
CAGCAATCTTCCAG-3′], andRev [5′-CAATGAAGTC-
TCGTCCATACTTCC-3′]; amplicon of 511 bp). Radio-
active in situ hybridization using [33P]-labeled probes 5′
(Nhs5) and 3′ (Nhs4) to the lacZ insertion site was per-
formed as described elsewhere (Thomas et al. 2000).
Generation and Analysis of a Mouse Nhs lacZ
Insertion Mutant
The mouse line 414, carrying a lacZ reporter gene in
the Nhs locus, was generated in a gene-trap screen (Voss
et al. 1998) through use of the splice-acceptor gene-trap
construct pGT1.8geo (Skarnes et al. 1995). The inser-
tion event occurred in the ﬁrst intron. The Nhs exon 1
upstream of the gene trap insertion was identiﬁed by 5′
RACE (Voss et al. 1998) and was conﬁrmed by northern
analysis (data not shown). The gene trap construct con-
tained a lacZ reporter gene, enabling the study of Nhs
promoter activity. b-galactosidase staining was per-
formed as described elsewhere (Voss et al. 1998).
Results
We investigated the original Australian kindred with
NHS (Horan and Billson 1974) and a further ﬁve smaller
pedigrees with NHS. Clinical features from a range of
affected individuals in the present study are shown in
ﬁgure 1A. A further branch of the original kindred with
NHS was discovered, enabling the study of a six-gen-
eration family with 12 living affected individuals (family
1 in ﬁg. 1B). Two of the affected males have severe
intellectual impairment. We conﬁrmed the linkage to
Xp22.13 through the genotyping of 11 microsatellite
markers in the region (including 4 novel markers) and
through use of the MLINK and X-Linked GeneHunter
Plus programs. Recombination events reﬁned the critical
region to a 1.3-Mb interval between markers DXS1195
and DXS999 (ﬁgs. 1B and 2A), in agreement with an-
other recent study (Toutain et al. 2002). All exons of
the six characterized genes in the region (SCML1,
SCML2, RAI2, RS1, STK9, and PPEF1) were directly
sequenced in three affected individuals and in one un-
affected individual. No segregating mutations were
detected.
We investigated a novel candidate gene, LOC90334,
predicted by Genescan (Burge and Karlin 1997) with-
in the NHS minimal genetic interval and supported
by clustered ESTs (NCBI UniGene cluster numbers
Hs. 444940, Hs. 282164, andHs. 21470) frommultiple
tissues, including fetal eye, brain, kidney, and colon.
These UniGene clusters, as well as ESTs AL926872 (Da-
nio rerio) and BF776631 (Bos taurus), suggested that
the gene contained additional upstream exon(s). Char-
acterization of this novel gene has established that it con-
sists of nine exons transcribed as two mRNA isoforms,
A (8.7 kb encoding a putative 1,630–amino acid protein;
the major isoform) and B (7.7 kb encoding a putative N-
terminus truncated 1,335–amino acid protein, with
translation beginning in exon 4; the minor isoform)
(ﬁg. 2A). Exon 1 was detected in genomic sequence
AL845433, ∼350 kb upstream of exon 2, through use
of the EST AL926872 (D. rerio) and the TBLASTX
algorithm. Exons 2 and 3 (genomic sequence Z93242)
of isoform A were identiﬁed from EST BF776631 (B.
taurus). Exons 1–3 were conﬁrmed by RT-PCR from
human brain RNA. The 5′ end of isoform B (exon 1b
in ﬁg. 2A) was identiﬁed by 5′ RACE. Exons 4–8 were
identiﬁed by a combination of Genescan, clustered ESTs
(Hs. 444940, Hs. 282164, and Hs. 21470), and RT-
PCR. Intron-exon boundaries are given in table 1.
Oligonucleotide primers were designed to PCR am-
plify and directly sequence the nine exons of the gene,
along with the ﬂanking intron/exon boundaries and the
5′ and 3′ UTRs. A single-nucleotide insertion mutation,
2387insC, was identiﬁed in exon 6 and segregated with
the NHS phenotype in family 1 (ﬁgs. 1B and 2A). This
mutation causes a frameshift in the reading frame,
Ala796fs, and is predicted to result in a premature stop
codon following the addition of 35 amino acids. A fur-
ther ﬁve families (ﬁg. 1B) with typical NHS were re-
cruited, and truncation mutations were also detected in
four of these families. A single-nucleotide deletion,
3459delC (Ala1153fs), was found in a second Austra-
lian family with NHS (Walpole et al. 1990) (ﬁgs. 1B
and 2A). It is interesting that a de novo nonsense mu-
tation, 1117CrT (Arg378X), was identiﬁed in an iso-
lated male infant with NHS (ﬁgs. 1B and 2A). The index
case of family 4 (ﬁg. 1B) displayed an unusually severe
ocular phenotype for a female with NHS. Two sequence
variations were identiﬁed: 718insG (Glu240fs) at the
ﬁrst base of exon 3, leading to a frameshift predicted
to result in a premature stop codon following the ad-
dition of 16 amino acids; and a base substitution,
IVS23CrG, at the 3′ acceptor splice site (ﬁg. 2A). The
signiﬁcance of the latter change is uncertain, but it was
not detected in 200 control chromosomes analyzed. The
affected mother of the proband displays the same ge-
notype. A single-base deletion, 400delC (Arg134fs), was
identiﬁed in family 5 (ﬁgs. 1B and 2A). It is notable
that this mutation is telomeric with regard to (and de
facto, outside of) the minimal critical region as deter-
mined in family 1 (the same critical interval was also
determined by an independent group, Toutain et al.
Figure 1 Families studied. A, Clinical features in individuals with NHS from the current study. Family 1, V-5: dentition (A.A), and cataract
(A.B); family 5, II-2: dentition (A.C), and facial features (A.D); family 4, II-1: dentition (A.E); and family 4, I-1: cataract (A.F). Dental anomalies
in the cases illustrated are diastema and notched incisors, showing striking similarity in three unrelated individuals. B, Pedigrees of the families
with NHS. Xp22.13 haplotypes are shown for family 1, with the common haplotype boxed and recombinations indicated with an “x.” Blackened
boxes denote affected males, blackened circles denote females with conﬁrmed features of NHS, and unblackened boxes and circles denote
unaffected males and females, respectively. ? p not available for examination.
Figure 2 Localization and characterization of the NHS gene. A, Schematic map of the Xp22.13 region, indicating positions of ﬂanking
markers and positions of candidate genes excluded, together with the structure of theNHS gene. Exon 1b deﬁnes a new putativeNHS transcription
start site. Note that markers DXS1195 and DXS418 are intragenic, residing in introns 1 and 5 of the NHS gene, respectively. Blackened segments
indicate the ORF. Sequence chromatograms and positions of ﬁve truncation mutations identiﬁed in families 1–5 are shown. Blackened boxes
next to chromatograms indicate affected males, blackened circles indicate affected females, and unblackened boxes indicate unaffected controls.
B, Partial ClustalW multiple-protein alignment of NHS orthologs. Protein sequence encoded by exons 1–4 (upper panel) and exon 5 (lower
panel) are shown. Mutations are indicated by arrows, and the nuclear localization sequence NLS1 is underlined. Conserved amino acid residues
are boxed. Family numbers correspond to those in ﬁg. 1B. Exon/exon boundaries are indicated with arrowheads and the corresponding exon
numbers. The mouse protein sequence was based on mouse genomic sequences (AL672082, AC097354, AL732391, and AC093447) andmouse
partial mRNAs similar to Nhs (XM_142285 and XM_112126).
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Table 1
Intron/Exon Boundaries of the NHS Gene
Exon 3′ Acceptor Splice Site 5′ Donor Splice Site
Exon Size
(bp)
1 GAGGCAGTGCgtgagtaccc 903
2 tgtcttgcagCCGTCTCCAA CTGCGCAGAGgtgacagatc 153
3 tccttctcagAACACCGGAG CTTTTTAACGgtaagtttgg 134
1b CTCTGACAAGgtaagtaaat 138
4 ttgtttgcagTCCCATCCCC AATGTTACTGgtatcgttct 193
5 tgggttgcagGAGTTGGCTT CAAGAAATAGgtgtgatatc 132
6 tgtgccctagATTCTGATGA TCATTGAAAGgtcagtcact 2,982
7 ttattttaagAATCATCACC TCATTCACAGgtgaggcaac 127
8 tttctcaaagATCCAAGAGG GCAAATAAACGTGACTGCA 4,134
NOTE.—Exons are indicated in capital letters, and introns are indicated in low-
ercase letters. Consensus ag/gt intron splice sites are underlined.
[2002]). The marker DXS1195 lies within the large,
∼350-kb intron 1 of the NHS gene (ﬁg. 2A). All ﬁve
mutations detected to date would result in a substantial
C-terminal truncation of the predicted NHS protein and
were not detected in 200 control chromosomes. No cod-
ing region or splice-site nucleotide changes were de-
tected in family 6.
Database searches revealed NHS orthologs in other
vertebrate species, including mouse, rat, cow, chicken,
zebraﬁsh, and frog. Protein similarity between the NHS
orthologs is relatively high, with the human protein
76%, 76%, 50%, and 46.5% identical to the mouse,
rat, zebraﬁsh (partial), and frog (partial) proteins, re-
spectively (ﬁg. 2B). The NHS protein shows no signif-
icant similarity to any known protein or class of pro-
teins. Four conserved putative monopartite nuclear
localization signals (Robbins et al. 1991) were detected
at amino acid positions 371–379 (RRRKLRRRK), 438–
444 (PSRRRIR), 822–825 (RKPK), and 1026–1034
(PGGSKRKPK), suggesting a functional role in the cell
nucleus (ﬁg. 2B and results not shown).
To study the expression of the NHS gene, human
adult and fetal multiple-tissue northern blot ﬁlters (Clon-
tech) were hybridized with three independent NHS
probes. Two major transcripts, of ∼8.7 kb and ∼7.7 kb,
were detected at low levels in all tissues analyzed (results
not shown). RT-PCR analysis of RNA from human
adult and fetal brain, lens, retina, retinal pigment epi-
thelium, placenta, lymphocytes, and ﬁbroblasts revealed
the presence of NHS transcript in all tissues, although
the transcript levels in retinal pigment epithelium, pla-
centa, lymphocytes, and ﬁbroblasts were very low (ﬁg.
3A and data not shown). To assess the developmental
expression pattern of the Nhs gene, a mouse northern
blot (Seegene) containing brain RNA from different de-
velopmental stages was probed. As shown in ﬁgure 3B,
the mouse Nhs gene is broadly expressed throughout
brain development and in the adult mouse brain, from
E17.5 until age 12 mo, although the transcript levels
vary. In situ hybridization of mouse embryo sections
showed that Nhs expression was developmentally reg-
ulated in a range of embryonic tissues (ﬁg. 3C). The
Nhs5 probe, generated from exon 1 (see the “Subjects
and Methods” section), detected expression in the mid-
brain, the lens and retina, the tooth primordia, the ol-
factory epithelium, and the whisker follicles. The Nhs4
probe, generated from exon 6, detected expression in
all these domains, as well as in the choroid plexus and
the heart (ﬁg. 3C).
To further study the expression proﬁle ofNhs through-
out development, we studied a mouse line containing a
lacZ reporter-gene cassette inserted in the Nhs locus.
The gene-trap insertion in intron 1 did not prevent tran-
scription and normal splicing of Nhs exons 3′ to the
insertion site. Therefore, this insertion event did not
completely disrupt the synthesis of a full-length Nhs
mRNA (data not shown). The Nhs gene (as traced by
lacZ expression) showed a complex pattern of expres-
sion. It was ﬁrst visible in the ventral neural tube at
E9.5 (not shown). At E10.5, the expression in the ven-
tral neural tube became stronger, and additional do-
mains of expression—including the heart—appeared
(ﬁg. 4A). At E11.5 and E12.5, expression was seen in
the olfactory epithelium, in the ventral aspects of the
maxillary process, and in the dorsal aspects of the man-
dibular process (ﬁg. 4B and 4C). Reporter-gene ex-
pression was most striking in the lens tissue, in which
cataract is a hallmark of the NHS phenotype. Expres-
sion in the lens vesicle was ﬁrst visible at E11.5 (ﬁg.
4B), became stronger at E12.5 (ﬁg. 4C), and persisted
until at least E16.5 (ﬁg. 3C.C). b-galactosidase protein
was seen throughout the primary lens ﬁbers (ﬁg. 4D).
Reporter-gene activity was veriﬁed as a true reﬂection
of the endogenous gene activity by parallel in situ hy-
bridization using probes 5′ (Nhs5) and 3′ (Nhs4) of the
reporter-gene insertion at one embryonic, one fetal, and
one postnatal stage. The reporter-gene expression was
found to associate with the lens ﬁbers; however, the
Figure 3 Expression analysis of the NHS gene. A, RT-PCR from human adult brain, fetal brain, retina, and lens tissues. RNA was reverse
transcribed and ampliﬁed using primers from exons 6 and 8. RT-minus controls were negative for each tissue. B, Mouse northern blot (Seegene),
containing 20 mg of total RNA per lane from mouse brain at various developmental stages. The probe was generated from the 3′ end of the
mouse Nhs gene. C, Mouse Nhs is developmentally regulated and is expressed in the brain, eye, and tooth primordia. C.A, Midsagittal section
from E16.5 mouse embryo, showing Nhs expression in the choroid plexus of the fourth ventricle. C.B, Parasagittal section of E14.5 mouse
embryo, showing Nhs expression in the midbrain. C.C, Sagittal section from E16.5 mouse embryo, showing expression in lens cell bodies
(arrow) and retina (arrowhead). C.D, Sagittal section from E16.5 mouse embryo, showing Nhs expression in the primordium of upper right
incisor tooth (arrow) and the whisker follicles (arrowhead). C.E, Detail of panel D, showing Nhs expression in the primordium of upper right
incisor tooth (arrow). C.F, Parasagittal section from E16.5 mouse embryo, showing Nhs expression in the primordia of the upper and lower
right molar teeth (arrows). C.G, Midsagittal section from E14.5 mouse embryo, showing Nhs expression in the right ventricle of the heart
(arrow). C.H, Parasagittal section from E14.5 mouse embryo, showing NHS expression in olfactory epithelium (arrows). The Nhs4 probe was
used in panels A and G, and the Nhs5 probe was used in panels B, C, D, E, F, and H.
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Figure 4 Expression analysis of the Nhs locus, using the lacZ reporter gene. Shown is b-galactosidase staining of a parasagittal section
of an E10.5 embryo (A), a whole-mount E11.5 embryo (B), a whole-mount E12.5 embryo (C), and a coronal section of an E12.5 eye (D);
radioactive in situ hybridization of a coronal section of E12.5 eye using the Nhs5 probe (E) and bright ﬁeld of E (F); b-galactosidase staining
of whole-mount PN0 brain (dorsal aspect) (G), whole-mount PN0 brain (ventral aspect) (H), adult brain (slice at frontal level) (I), and adult
brain (slice at parietal level) (J). AER p apical ectodermal ridge; AN p amygdaloid nuclei; ANP p amygdaloid nuclei primordium; Co p
cortex; dMan p dorsal mandibular process; He p heart; Hi p hippocampus; Hy p hypothalamus; Lep lens; LCBp lens cell bodies; LVp
lens vesicle; Medp medulla; Mesp mesencephalon; NRp neural retina; OBp olfactory bulb; OEp olfactory epithelium lining the olfactory
pit; ON p optic nerve; OT p olfactory tubercle; Po p pons; PR p pigmented retina; SN p septal nuclei; TG p trigeminal ganglion; vMax
p ventral maxillary process; vMes p ventral mesencephalon; vNT p ventral neural tube; vSC p ventral spinal cord.
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endogenous Nhs mRNA is restricted to the cell bodies,
as expected (ﬁg. 4E and 4F). Sense probes did not show
any signal above background (data not shown).
An intricate pattern of Nhs promoter activity was
seen in the early postnatal brain. Reporter-gene activity
was detected in the ventral neural tube and in its de-
rivatives from the level of the midbrain extending to the
tail (ﬁg. 4A, 4C, and 4H). Strong expression was found
in the olfactory epithelium (ﬁg. 4B and 4C) and in the
olfactory bulbs and medulla (ﬁg. 4G and 4H). Partic-
ularly striking were strong domains of reporter-gene ac-
tivity in aspects of the limbic system of the adult brain.
These included expression in the septum, as well as in
the amygdala and the hypothalamus (ﬁg. 4H, 4I, and
4J). Lower levels of expression were seen in the cortex
and hippocampus (ﬁg. 4J). Reporter-gene activity was
also noted in the heart (ﬁg. 4A, 4B, and 4C), the apical
ectodermal ridge (ﬁg. 4B and 4C), and the olfactory
tubercle (ﬁg. 4I).
Discussion
We used a positional cloning strategy to delineate a 1.3-
Mb critical interval, between markers DXS1195 and
DXS999, conﬁning the gene for NHS, and we subse-
quently characterized a large novel gene, without sig-
niﬁcant homology to other genes, that resides predom-
inantly within the critical interval. The disease interval
was entirely determined from recombination events in
one very large pedigree. Since a branch of this family
formed the basis for one of the two original studies of
NHS (Horan and Billson 1974), we felt conﬁdent that
the disease gene would indeed be conﬁned between these
two markers. A recent study (Toutain et al. 2002) con-
ﬁrmed the same disease interval through use of recom-
binations in different families. It was interesting to note
that, after characterizing the NHS candidate gene and
ﬁnding mutations in four pedigrees, a ﬁfth family with
features very typical of NHS had no identiﬁed mutation.
Further detailed analysis of the gene structure revealed
the presence of another exon, ∼350 kb upstream. A trun-
cating mutation was detected in this exon, which is telo-
meric to marker DXS1195 (present in intron 1). Con-
sequently, the causative mutation in this family lies
outside the minimal genetic interval as determined in
family 1 and in the study by Toutain et al. (2002), thus
illustrating the potential limitations of critical intervals
for those involved in positional cloning studies.
The affected individuals from all families involved in
the present study had features typical of NHS. The pres-
ence of a de novo mutation in a male infant with NHS
indicates that mutations in the NHS gene may cause
congenital cataract, despite the absence of a positive
family history. Mutations were found in a total of ﬁve
of six families with features typical of NHS. Despite
detailed analysis of family 6, no mutation has been iden-
tiﬁed in the coding sequence, intron-exon boundaries,
or the 5′ and 3′ UTR. This family may have an intronic
or noncoding regulatory mutation that has not been
identiﬁed as yet. Alternatively, there may be genetic het-
erogeneity in NHS.
It is noteworthy that all of the mutations described
led to signiﬁcant truncation of the carboxy terminus of
the predicted protein. The mutations found in the fam-
ilies with NHS are located throughout the gene, and
there was no obvious genotype/phenotype correlation
between mutation position and severity of disease. It
should also be noted that a wide variation in the degree
of severity of ocular manifestations and mental retar-
dation occurred within family 1, raising the possibility
of genetic modiﬁers. The mutations identiﬁed in families
4 and 5, located in exons 3 and 1, respectively, indicate
that loss of the major NHS isoform A is sufﬁcient to
cause disease. The phenotype in families 4 and 5 is sim-
ilar to that in other families with NHS, indicating that
there is no obvious correlation between the loss of only
isoform A and severity of disease. Similarly, we found
no obvious differences in the phenotype of individuals
in whom mutations remove all four nuclear localization
signals (families 4 and 5) and those in whom these se-
quences are not affected (family 2). Therefore, it is likely
that the phenotype is caused, at least in part, by loss of
function, either through mRNA degradation or protein
truncation, rather than simply by loss of subcellular
localization.
NHS is a large gene of unknown function that en-
codes a predicted 1,630–amino acid protein lacking se-
quence similarity to any other known protein or protein
classes. The identiﬁcation of nuclear localization sig-
nals, along with the high serine and proline content
(24%) and the pleiotropic features of the NHS phe-
notype, support a regulatory role for the NHS protein
in the development of ocular, craniofacial, and neural
tissue. Conservation in other vertebrate species, such as
mouse, rat, and zebraﬁsh, supports an important role
for NHS in development. We have performed detailed
studies of the expression pattern of NHS, in fetal and
adult derived tissue from human and mice. These in-
dicated low levels expression in all tissues analyzed, in-
cluding human adult lens tissue. The ﬁnding of different
expression levels in the developing mouse brain at dif-
ferent developmental stages led us to further investigate
the broader developmental expression proﬁle in mice,
through use of in situ hybridization studies. These stud-
ies suggested an intricate pattern of spatially and de-
velopmentally regulated expression, particularly as ex-
pected in tissues known to be affected in NHS, such as
the lens, brain, craniofacial mesenchyme, and dental
primordia.
To further study the developmental expression pat-
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tern, we analyzed a mouse line containing a lacZ re-
porter-gene cassette inserted in the Nhs locus. This en-
abled sensitive detection of expression driven by theNhs
promoter. Striking expression in the developing lens was
demonstrated, consistent with a role in lens develop-
ment. In the developing and early postnatal brain, the
presence of relatively high levels of expression in some
tissues—in particular, the olfactory bulbs, olfactory ep-
ithelium, and limbic system—was striking. These ﬁnd-
ings raise the possibility that NHS is of importance in
development of the limbic system, which is of interest
given the range of neuropsychological abnormalities re-
ported in some males affected with NHS. These ab-
normalities include (in addition to the well documented
incidence of mental retardation) autism, aggression,
anxiety, stereotypical behavior, mood disturbance (e.g.,
unprovoked laughter), and sleep-wake cycle abnor-
malities (Toutain et al. 1997a). Our ﬁnding of Nhs
expression in the heart is also of interest, since a family
was recently reported as having X-linked cataract as-
sociated with cardiac anomalies mapping to this region
of chromosome Xp22 (Francis et al. 2002). It has been
postulated that isolated X-linked cataract andNHSmay
be allelic, because of the similarity in the cataract phe-
notype and the overlapping critical regions on the X
chromosome (Francis et al. 2002). The mouse ortholog
of NHS is a strong candidate for the Xcat mouse phe-
notype, which maps to the syntenic region of chro-
mosome Xp (Favor and Pretsch 1990). The Xcat mouse
displays only an ocular phenotype of bilateral total lens
opacity in males, with varying severity of nuclear and
cortical opacity in heterozygous females. Further anal-
ysis is also required to determine whether NHS has a
role in isolated X-linked mental retardation, which is
known to be highly heterogeneous and, at least in some
cases, to map to Xp22 (Chelly and Mandel 2001).
Our ﬁndings and further studies to determine the
function of NHS will advance understanding of lens
development and cataract formation. The embryology
of lens development is well characterized, and a number
of different mechanisms of cataract formation are
known, with the best studied involving structural pro-
teins such as the crystallins (Litt et al. 1997). Mutations
in genes encoding proteins involved in ion transport
(Shiels and Bassnett 1996) are also known to cause con-
genital cataract. Disturbance of metabolic pathways in
galactosemia are well characterized causes of lens dys-
function resulting in cataract (Stambolian et al. 1995).
Aberrations in developmental pathways resulting in cat-
aract are less well understood; however, more recently,
mutations in genes such as PAX6, PITX3, and MAF
have been described in which congenital cataract is at
least one of the features. (Semina et al. 1998; Hanson
et al. 1999; Jamieson et al. 2002).
In summary, we present evidence that mutations in a
novel gene of as-yet-unknown function, which we have
named “NHS,” cause the pleiotropic features of NHS.
The lack of sequence similarity between the NHS pro-
tein and any other known protein or protein classes
suggests that the NHS gene may form a novel com-
ponent of the genetic program controlling ocular, cran-
iofacial, and CNS development. This work will enable
direct DNA diagnosis in families with blindness and
mental retardation due to NHS, leading to improve-
ments in genetic counseling and reproductive choices.
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